证券日报网讯 10月15日晚间，万泰生物发布公告称，公司于2025年10月15日召开第六届董事会第十次 会议、第六届监事会第十次会议，审议通过了《关于变更部分回购股份用途并注销的议案》。公司拟将 回购专用证券账户中已回购但尚未使用的729，970股股份用途由"用于员工持股计划或股权激励"变更 为"用于注销并减少注册资本"。 （文章来源：证券日报） ...

Core Viewpoint - Wantai Biological Pharmacy (万泰生物) announced a change in the use of 729,970 repurchased shares from "for employee stock ownership plan or equity incentives" to "for cancellation and reduction of registered capital" [1] Group 1 - The company aims to enhance the motivation of its management team and core technical and business personnel to strengthen its core competitiveness [1] - Wantai Biological will actively explore other feasible incentive plans and will consider launching equity incentives or employee stock ownership plans when market conditions and actual situations are favorable [1] - The goal is to promote continuous efforts from core employees to create value for shareholders and support the company's healthy and sustainable development [1]

证券代码：603392 证券简称：万泰生物 公告编号：2025-049 北京万泰生物药业股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (七)涉及公开征集股东投票权 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 10 月 31 日 14 点 00 分 召开地点：北京市昌平区科学园路 31 号公司会议室 (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年10月31日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 10 月 31 日 至2025 年 10 月 31 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-047 北京万泰生物药业股份有限公司 第六届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 1、审议通过了《关于变更部分回购股份用途并注销的议案》 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7 号——回购股份》等相关规定，为严格履行公司回购股份方案中关于回购股份使 用期限的相关承诺，将尚未用于员工持股计划或股权激励用途的股份及时注销并 相应减少注册资本，同时基于对公司未来持续稳定发展的信心和对公司长期价值 的认同，为切实维护广大投资者利益，提高公司长期投资价值，增强投资者对公 司的信心，同意公司将回购专用证券账户中已回购但尚未使用的729,970股股份 用途由"用于员工持股计划或股权激励"变更为"用于注销并减少注册资本"。 为充分调动公司管理团队与核心技术、业务人员的积极性，增强公司的核心 竞争力，公司将积极探索其他可行的激励方案，公司后续将结合市场环境和实际 情况，待条件成熟择机启动股权激 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-046 北京万泰生物药业股份有限公司 第六届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月15日以 通讯方式召开第六届董事会第十次会议。根据《公司章程》和公司《董事会议事 规则》的有关规定，本次会议豁免通知时限要求，公司于2025年10月15日以专人 送达、电话等方式通知全体董事。本次会议由公司董事长邱子欣先生主持，应出 席董事7人，实际出席董事7人。本次会议的出席人数、召开和表决方式符合《公 司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于变更部分回购股份用途并注销的议案》 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7 号——回购股份》等相关规定，为严格履行公司回购股份方案中关于回购股份使 用期限的相关承诺，将尚未用于员工持股计划或股权激励用途的股份及时注销并 相应减少注 ...

Group 1 - The company WanTai Bio announced on October 15 that its sixth board meeting will be held via communication on October 15, 2025 [1] - The meeting will review the proposal to convene the company's first extraordinary general meeting of shareholders in 2025 [1] Group 2 - The news highlights a significant opportunity in the silver rental market, with annualized interest rates soaring to 35% [1] - There is a global trend of silver being airlifted to the UK for profit, indicating a major squeeze in the market [1]

证券代码：603392 证券简称：万泰生物 公告编号：2025-048 北京万泰生物药业股份有限公司 关于变更部分回购股份用途并注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 变更部分回购股份用途：北京万泰生物药业股份有限公司（以下简称"公司"） 拟将回购专用证券账户中已回购但尚未使用的729,970股股份用途由"用于员工持股计 划或股权激励"变更为"用于注销并减少注册资本"。 拟注销股份数量：729,970股，占公司当前总股本的比例为0.0577%。 本次变更部分回购股份用途并注销事项尚需提交公司股东会审议通过后实施。 公司于2025 年10 月15 日召开第六届董事会第十次会议、第六届监事会第十次会议， 审议通过了《关于变更部分回购股份用途并注销的议案》。公司拟将回购专用证券账户 中已回购但尚未使用的 729,970 股股份用途由"用于员工持股计划或股权激励"变更为 "用于注销并减少注册资本"。现将有关事项公告如下： 一、回购股份方案及实施情况 容详见公司于2022年12月23日在指定信息披露媒 ...

Core Insights - The first domestically produced nine-valent HPV vaccine was approved for market release in June, highlighting the innovative capabilities of Wantai Biological Pharmacy [1] - Wantai Biological emphasizes innovation as its core competitive advantage, investing over 1 billion yuan annually in R&D, with over 30% of its workforce dedicated to research [2] - The company has developed hundreds of products, including six global firsts and seven domestic firsts, contributing significantly to public health and national strategic competitiveness [2] Innovation and Product Development - Wantai Biological has over 300 patents, with more than 100 receiving international certification, showcasing its commitment to innovation [2] - The company’s unique hepatitis E vaccine, Yikening, is the only one of its kind globally, demonstrating its capability to fill market gaps [3] - The newly approved nine-valent HPV vaccine, Xinkening 9, is priced at 499 yuan, approximately 40% lower than imported alternatives, enhancing accessibility for women aged 9 to 45 [3] Vaccine Pipeline and Market Strategy - Wantai Biological has a diverse vaccine pipeline, including 20-valent pneumonia conjugate vaccine and recombinant zoster vaccine, among others, indicating a robust development strategy [4] - The company is advancing its production automation and digital transformation to enhance efficiency and quality in its manufacturing processes [5][6] International Expansion and Market Presence - In 2024, Wantai Biological's overseas revenue reached 216 million yuan, a 42.59% increase, reflecting its successful internationalization efforts [6] - The company aims to obtain WHO PQ certification for its nine-valent HPV vaccine, leveraging its existing international achievements to expand its global market presence [7] - Wantai Biological is focused on transitioning from product export to global health empowerment, aiming for diversified revenue structures and enhanced brand value [7]

Core Insights - The first domestically produced nine-valent HPV vaccine was approved for market release in June, marking a significant milestone for Wantai Biological Pharmacy [1] - The company emphasizes innovation as its core competitive advantage, investing over 1 billion yuan annually in R&D, with over 30% of its workforce dedicated to research [2] - Wantai has developed hundreds of products, including six global firsts and seven domestic firsts, contributing to public health and national strategic competitiveness [2] Company Overview - Founded in 1991, Wantai Biological is a high-tech enterprise focused on the research and production of biological diagnostic reagents and vaccines [2] - The company operates seven subsidiaries and offers a wide range of products across various fields, including automation, biochemistry, and vaccines [2] Product Innovations - The company’s Hepatitis E vaccine, Yikening®, is the only marketed Hepatitis E vaccine globally, demonstrating a 100% protection rate one year after a three-dose regimen [3] - The newly approved nine-valent HPV vaccine, Xinkening®9, is priced at 499 yuan per dose, approximately 40% lower than imported alternatives, providing broader access for women aged 9 to 45 [3] R&D Pipeline - Wantai is advancing multiple innovative research pipelines in the vaccine sector, including a 20-valent pneumonia conjugate vaccine and a recombinant zoster vaccine [4] Production and Automation - The company has enhanced its production line automation to efficiently convert research outcomes into high-quality products, despite challenges in the industry [5] - Wantai is progressing towards becoming a digital factory, evaluating digital transformation solutions to improve production efficiency [6] International Expansion - In 2024, Wantai's overseas revenue reached 216 million yuan, a 42.59% increase, with its core product, the bivalent HPV vaccine, gaining market access in 23 countries [6] - The company aims to achieve WHO PQ certification for its nine-valent HPV vaccine and expand its global network to support cervical cancer elimination strategies [7]

Core Viewpoint - Wante Bio's stock price has experienced a decline of 18.10% year-to-date, with recent fluctuations indicating a slight recovery in the short term [1] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [1] - The main revenue composition includes diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active ingredients (0.76%) [1] Financial Performance - As of June 30, 2025, Wante Bio reported a revenue of 844 million yuan, a year-on-year decrease of 38.25%, and a net profit attributable to shareholders of -144 million yuan, a year-on-year decrease of 155.30% [2] - Cumulative cash dividends since the A-share listing amount to 1.541 billion yuan, with 1.311 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 24.00% to 38,400, while the average circulating shares per person decreased by 19.36% to 32,958 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 22.7544 million shares, an increase of 5.1508 million shares from the previous period [3]